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Abstract
Malaria is one of several neglected diseases characterized by parasitic infection of global 
importance present in tropical countries. Malaria is caused by protozoa, belonging the genus 
Plasmodium and the vector for the transmission of the disease are female of the Anopheles 
mosquitoes infected with the Plasmodium ssp. According the World Health Organization 
(WHO), there was 219 million malaria cases worldwide in 2017, and approximately 435 000 
malaria deaths in the same year. The increasing resistance to treatment has posed a major 
problem since the beginning of the 21st century, and with this, new research has been done with 
the intention of finding a new drug to be used for the eradication of the disease. A new protein 
has been studied as a potential target drug in malaria, N-myristoyltransferase (NMT), and the 
NMT acts on myristoylation of proteins, facilitating the binding of these to the plasma 
membrane and also contributes to the stabilization of protein-protein interactions. By inhibiting 
NMT it has already been established that the cell of the parasite can be killed. Therefore, in 
order to predict and detect potential inhibitors against Plasmodium NMT, the bioinformatic 
tools were used in this work, encompassing the virtual screening, docking, validation and 
molecular dynamics. With the analysis performed during the work it was possible to obtain 
compounds with great similarity to the original ligand, thus being good potential inhibitors of 
Plasmodium NMT.
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1. Introduction
1.1. Malaria
Malaria is one of several neglected diseases characterized by parasitic infection of global 
importance present in tropical countries. It is also considered endemic mainly in low-income 
populations (Suh, Kain e Keystone, 2004). It is caused by protozoa belonging to the genus 
Plasmodium, which has five species capable of causing disease in humans: Plasmodium 
falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale and Plasmodium 
knowlesi (Bannister e Sherman, 2009). The cases of disease that led to death are related to P. 
falciparum, the other species of the genus Plasmodium cause a milder form of the disease 
(ASHLEY et al., 2006). There are reports of P. ovale and P. knowlesi in some regions of the 
African continent and in Southeast Asia. In Brazil there are reports only of the other species, 
being the P. vivax the most prevalent species (Lee e Vythilingam, 2013) (WHO, 2018).
The vectors responsible for the transmission of the disease are females of Anopheles 
mosquitoes infected with Plasmodium spp. The bite of this mosquito introduces the parasites 
into the skin then reach bloodstream of the individual which they migrate to the liver, become 
mature and reproduce (Beier, 1998). In the asexual cycle of the parasite, the mosquito vector 
transmits the parasite through the bit in the sporozoite stage. The sporozoite invade liver cells, 
where replication happens dividing into merozoites, thereafter, the liver cell that was infected 
suffers rupture, releasing the merozoites into the bloodstream, occurring invasion of the red 
blood cells, thus configuring the beginning of the asexual blood stage, which is the symptomatic 
phase of disease. Individuals perceive the symptoms of the disease in a period of 8 to 25 days 
after the vector inoculation. However, the signs of malaria are nonspecific, with fever being the 
main sign, making it difficult to distinguish easily from another diseases that also cause fever 
(Burchard, 2014). Fever occurs when the infected red blood cells suffer lyses and release a 
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massive endotoxin. (PHILLIPS et al., 2017) (Figure 1). Another very common symptom is 
paroxysm (cyclic occurrence of sudden coldness followed by tremors and subsequently fever 
and sweating) in P. vivax infections which is the main parasite of this work ( TOUZE, JE. et 
al., 1998).
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Figure 1. Asexual cycle of the Plasmodium ssp. Adapted by: “Malaria” (Phillips et al., 2017).
Usually, the disease is diagnosed through light microscopy of thick and thin stained blood 
smears and rapid antigen-based tests. The treatment of choice will depend on the severity of the 
disease. This treatment involves the use of artemisinin-based therapies combined with 
conventional antimalarials, such as chloroquine, sulfadoxine-pyrimethamine and amodiaquine 
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(White et al., 2014). The increasing resistance to the current treatment has posed a serious 
problem of public health in endemic, but new potential drugs have emerged to delay the spread 
of the disease (Greenwood et al., 2014).
Recently the protein N-myristoyltransferase (NMT) has been studied as a potential target 
drug in malaria (Brannigan et al., 2014; Price et al., 2003). The NMT catalyzes the transfer of 
myristoyl-CoA myristate fatty acid to glycine from the amino terminal portion of a set of 
proteins (Sonnenburg e Gordon, 2013). Myristoylation of proteins facilitates the binding of 
these to the plasma membrane and also contributes to the stabilization of protein-protein 
interactions. There is high sequence homology between human (HsNMT) and parasite protozoa 
NMT (PvNMT), and myristoyl-CoA binding sites are highly conserved among species. There 
is, however, a divergence between the binding sites of the peptide substrates between the human 
species and parasitic protozoa that can be exploited to search for specific inhibitors for 
pathogens (Resh, 2012). The NMT was successfully used as a drug target in Trypanosoma 
brucei by (Frearson et al., 2010), which found inhibitors that bind with high affinity to the 
peptide substrate site, inhibiting N-myristoylation in trypanosome. NMT is thus an appropriate 
target for the search for therapies against parasitic protozoa including those responsible for 
malaria.
Currently, many research groups have focused their studies on the search for new 
therapeutic agents, with an emphasis on cheaper compounds that have lower toxicity when 
compared to frequently used drugs. One of the strategies in this sense is the search for potential 
drugs in libraries of compounds already available, provided by the companies producing these 
new molecules. This search can be performed by means of virtual sorting of compounds with 
the aid of computational methods such as modeling of pharmacophores and molecular docking.
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1.2. Bioinformatics
1.2.1. Pharmacophores
Pharmacophores are, by their most current definition, a set of steric and electronic 
characteristics that are necessary to ensure optimal supramolecular interactions with a specific 
biological target, activating or blocking their biological response (Wermuth et al., 1998). The 
central pharmacophore concept involves the notion that the molecular recognition of a 
biological target by a group of compounds can be attributed to a small set of common 
characteristics that interact with complementary regions in the biological target, these being 
quite general characteristics: hydrogen bonds, hydrogen bond acceptors, positively and 
negatively charged groups, and hydrophobic regions (Leach et al., 2010).
There are basically two methods of modeling pharmacophores, the structure-based and 
the ligand-based. Structure-based uses information on protein-binding or protein-only 
interactions, obtained from an experimentally derived 3D structure, to generate a model. The 
ligand-based method extracts information from the model only from the ligand, obtaining 
common chemical characteristics in active compound assemblies or only the use of a single 
compound that serves as a template for the elucidation of the pharmacophore (McGann, 2011).
Pharmacophore modeling is a well-established in silico technique that generates many 
benefits for initial research with drug designs. Its advantages are the visualization of the 
chemical characteristics supposedly important in the protein-ligand interaction as well as the 
obtaining of structurally diverse bioisosteric compounds that would not have been discovered 
by systematic derivatization of existing compounds (Markt, Schuster e Langer, 2011). The 
growing range of applications of pharmacophores, together with cases of success in drug 
discovery, has allowed the enrichment of the concept of pharmacophore by promoting the 
development and application of new approaches (Yang, 2010). Other strategy similar to 
pharmacophore modeling is the shape-based models. Shape-based modeling aims to extract not 
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only the common chemical characteristics but also the shape of the ligands used as query, thus, 
producing very refined models.
1.2.2. Molecular Docking
Molecular docking involves the search for modes of interaction between two molecules, 
such as protein-protein, protein-ligand, or protein-DNA interactions. The macromolecular 
protein-ligand docking system consists of two steps: a conformational search algorithm that 
involves all degrees of freedom of the ligand (translational, rotational, and conformational) and 
a scoring function that ranks the probable spatial positions for a compound or several from a 
large library (Rognan, 2011).
1.2.3. Molecular Dynamics
Molecular dynamics represents the computational approach to statistical mechanics and 
is used to estimate equilibrium and dynamic properties of complex systems that cannot be 
calculated analytically (Shlick, 2010). Understanding the movements of proteins has been an 
important field of research, since the dynamics are inexorably linked to their function (Samish, 
Gu e Klein, 2009).
1.2.4. Justification
Protein-ligand docking was one of the pioneer methodologies in the 1980s in 
bioinformatics analyzes (Kuntz et al., 1982) and when only the structure of a target and its 
binding site are available, high performance docking is the first choice as a tool for identifying 
drug candidates. Although docking and scoring functions are based on approximations, the 
application of these techniques during the optimization of lead compounds together with other 
computational methods adds up to traditional approaches in the design of drugs based on 
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structure (Kitchen et al., 2004). Currently, the dominant technique for identifying new leading 
compounds in drug discovery is the physical prospection of large substance libraries against a 
biological target. An alternative approach, known as virtual screening, is to search 
computationally large libraries of compounds that target a known structure, and experimentally 
test those that have good interactions (Shoichet, 2004).
Since malaria is an endemic and tropical disease that affects mainly low (African 
continent and part of the Asian continent) and middle income countries, such as Brazil, and 
several cases of death due to this disease worldwide have been reported, this research was 
conducted in order to contribute in the proposal of a practical and economical approach in the 
search of effective drugs against Pv-NMT protein. To do this, we used databases of proteins 
and ligands available to the scientific community, as well as computational strategies and tools 
to search for compounds with pharmacological potential against malaria.
2. Objectives
2.1. General Objectives
Search for potential ligands for the three-dimensional structure of the Plasmodium vivax 
N-myristoyltransferase enzyme through the construction of a shape-based model, virtual 
screening, molecular docking and molecular dynamics.
2.2. Specific Objectives
o Construct a shape-based model based on the structure of the ligands extracted from a 
complex with the N-myristoyltransferase protein;
o Perform a shape-based search through virtual screening in a conformer library of small 
ligands.
o Analyze the receptor-ligand interaction between the P.vivax N-myristoyltransferase and 
the selected compounds in the virtual screening, through the molecular docking technique.
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o Ranking molecular docking results of the protein-ligand complexes using specific 
scoring functions.
o Evaluate the potential toxic, in silico, properties of the selected compounds.
o Perform the molecular dynamics in the protein-binding complex of the selected 
compounds, in order to measure the stability of the interaction.
3. Material and Methods
For a better understanding, according to Figure 2, the ligands in complex with the 
PvNMT of the Protein data bank site were initially found, thus allowing the alignment of 
these molecules together with the generation of the active and decoys molecules, which are 
fundamental for the generation of the validated pharmacophoric model. With the generated 
model and the prepared compound libraries, it was possible to perform the virtual screening, 
molecular anchoring, pkCSM analysis and the Molecular Dynamics. Each topic will be 
covered in specific throughout the text.
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3.1. Generation of shape-based model based on the ligand form
In order to perform a virtual screening against the ligand libraries, a shape-based model 
was generate based in ligands, extracted from NMT structural complexes, present on the Protein 
Data Bank (PDB) - PDB IDs: 4B12, 4B13, 4B14, 4BBH, 4CAE, 4CAF. This step was 
developed with the help of PharmaGist webserver (Schneidman-Duhovny et al., 2008) and 
ROCS 3.2.0.4 program, OpenEye Scientific Software, Santa Fe, NM (Hawkins, Skillman e 
Nicholls, 2007). PharmaGist was used to align the known inhibitors structures and ROCs was 
used to construct shape-based models based on the alignment. Also, ROCs is shape comparison 
method, based on the idea that molecules have similar shape if their volumes overlap properly. 
Although ROCS is primarily a shape-based method, the user can define for specific regions of 
the model, chemical characteristics described as: hydrogen donors, hydrogen acceptors, anions, 
cations, hydrophobic and regions of aromatic rings. In this way, the models that are formed 
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during the overlapping process facilitate the identification of the compounds which are similar 
in shape and in chemistry.
3.2. Conformers libraries generation
The shape-based model generated through the ROCS program was used in the virtual 
screening of compounds libraries originating from two databases. The first database belongs to 
Chembridge Corporation, San Diego, California, more specifically the DIVERSet ™ Cl, and 
this library has a total of 50.000 compounds of diversity druglike structures that are carefully 
selected to provide the widest coverage of the pharmacophoric space. The second library 
belongs to ZINC12 database (Irwin e Shoichet, 2005) more specifically the Zbd subset of 
natural products. These libraries were submitted to the FILTER program of OMEGA 2.5.1.4, 
OpenEye Scientific Software, Santa Fe, NM (Hawkins et al., 2010). FILTER is a rapid filtering 
and compound selection program that uses a combination of physical property calculations and 
functional group knowledge. It was used prior to experimental analysis to remove undesirable 
compounds such as compounds with toxic functions, with low oral bioavailability, with high 
probability of forming covalent bonds with the protein target and compounds with probability 
of interference in the experimental trial.
The compounds of the library filtered through FILTER were submitted to the program 
QUACPAC 1.6.3.1, OpenEye Scientific Software, Santa Fe, NM (http://www.eyesopen.com) 
in order to generate, for each molecule, precise charges at pH 7.4 and the probable tautomers. 
Finally, the compound libraries were submitted to the generation of conformers through the 
OMEGA program. OMEGA generates bioactive composite multi-conformer databases with 
high speed and reliability. The generation of conformers is an essential step for virtual screening 
using shape-based models, since these rely on bioactive conformations to achieve satisfactory 
results.
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3.3. Virtual screening and Validation
For accurate understanding, interpretation and comparison of virtual screening, ROCS 
contain methods of statistical validation of the results achieved in the screening. The ROC curve 
(receiver operating characteristic) and AUC (area under the curve) was used in this validation. 
The ROC curve represents the comparison of active compounds versus decoys (non-target 
protein binding ligands and potentially inactive) and AUC, extracted from the ROC curve 
graph, is simply the probability that a randomly selected active compound scores higher than 
an inactive compound chosen at random. For the construction of the ROCS curve and obtaining 
the AUC value, biologically active ligands found in the literature against the N- 
myristoyltransferase protein was used (Bell et al., 2012) . The decoys were generated on the 
DUD-E online platform (Mysinger et al., 2012) which uses active ligands to generate a set of 
decoys. In this way, it was possible to evaluate the quality of the shape-based model generated 
from the ligands (4B12, 4B13, 4B14, 4BBH, 4CAE and 4CAF) by overlapping and comparing 
the results between active ligands and decoys.
The shape-based model previously generated was used in the screening of Cl and Zbd 
libraries. Each screened libraries generated a subset of the best 500 molecules or the best 500 
hits, that is, the molecules with high overlap score to the model, called TanimotoCombo score.
3.4. Molecular Docking and Evaluation
The best 500 molecules, obtained from the shape-based model screening, were submitted 
to a molecular docking. For this purpose, the FRED program, OpenEye Scientific Software, 
Santa Fe, NM (McGann, 2011) was used. FRED performs a systematic and non-stochastic 
examination of all possible protein-ligand positions where these was ranked using the 
Chemgauss4 scoring function. Chemgauss4 measures the complementarity of the positions of 
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the ligand within the active site. To do so, it recognizes the following ways of interaction: shape; 
hydrogen bonds between ligand and protein; interactions of hydrogen bonds with implicit 
solvent and chelator interactions.
3.5. Analysis of toxic properties in silico
Following screening and molecular docking, an in silico approach was used to evaluate 
the toxicity properties of the selected compounds. To predict the pharmacokinetic properties of 
the compounds, a software online called pkCSM (Pires, Blundell e Ascher, 2015) based on 
graph-based signatures was used. The pkCSM signatures were successfully used in the five 
major classes of pharmacokinetic properties to develop predictive regression and classification 
models. This step is important to verify and predict if the potential inhibitors presents the 
acceptable parameters to drug selection and a possible administration in humans.
The results were judged by positive and negative pharmacokinetic characteristics, and in 
case of this work, was choose some in specific like AMES toxicity, Max tolerated dose 
(human), hERG I inhibitor, hERG II inhibitor, Oral Rate Acute Toxicity (LD50), Oral Rat 
Chronic Toxicity (LOAEL), Hepatotoxicity, Skin Sensitization and the Minnow toxicity.
The AMES toxicity parameter is a widely employed method to assess a potential 
mutagenic compound using in bacteria, so if the test is positive, that indicates that the compound 
in question is mutagenic and may act as a carcinogen.
The Maximum Tolerated Dose (human) parameter estimate the toxic dose threshold of 
chemical in humans (mg/kg/day), being less or equal to 0.477(mg/kg/day) considered as low 
and high if greater than 0.477(mg/kg/day).
The hERG I/II parameter analyses the long QT syndrome (LQTS), generated by the 
inhibition of the potassium channels and it can be a complication in the electrical cycle of heart, 
resulting is risks of sudden death, according if the result is positive or negative, but even if the 
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result is positive to the inhibition of these channel, depends for what the medicament will be 
used.
The Oral Rate Acute Toxicity (LD50) parameters refers to the lethal dosage values given 
all at once (LD50) that is necessary to cause the death of 50% of a group of test animals.
The Hepatotoxicity parameters refers a liver associated side effects observed in humans, 
being able to cause or not.
The Skin Sensitization parameters is a potential adverse effect for dermally applied 
products, being able to cause allergic response.
And as a last parameter, the Minnow toxicity refers at the lethal concentration values 
(LC50) necessary to cause the death of 50% of the “Flathead minnows” (species of fish used as 
an indicator of toxicity), and values below 0.5 mM are considered as high acute toxicity.
3.6. Molecular Dynamics
The ligands selected from the molecular docking results and the pharmacokinetic 
properties analysis were submitted to receptor-ligand molecular dynamics (DM) using the 
GROMACS program (Abraham et al., 2015). The parameters to generate the topology for each 
ligand were performed using SwissParam (Zoete et al., 2011), using the CHARMM force field. 
The MD of Protein-ligand complex were performed on GROMACS (Abraham et al., 2015), 
using CHARMM27 force-field, which is the recommended to use the TIP3P as water model. 
The unit cell was defined as triclinic shape, water and ions were added and energy minimization 
were performed and the solutions were subjected to 10 ns of simulation during the production 
phase of the dynamics under NTP conditions. The result of the dynamics was evaluated through 
tools provided by the GROMACS program. In this way, the deviation of the quadratic mean 
(RMSD) of the solution and the number of hydrogen bonds and free energy between the ligand 
and the binding site along the dynamics was evaluated.
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For molecular dynamics, a molecule with the best predictions in pkCSM was selected. 
The first step in DM was the preparation of the ligand and the topology generation of the 
protein. The preparation of the ligand and the protein was done by treating the molecules, where 
undesirable compounds (ions, cations, salts) have been removed and added hydrogens.
Once these basic treatments were done, the dynamics began, which consists of some steps 
for a simulation of this protein-ligand interaction within a biological system. Then after the 
topology generation, a water box was created to encompass the molecules to study the 
interaction. Thus, a solvated system was obtained, and ions were then added to that system in 
order to balance charges in it. Then, the last step began with a energy minimization procedure.
With the system minimized its balance was realized. Two conditions exist to carry out the 
equilibrium: restriction of the ligand and treatment of the temperature of the complex. The 
balance consisted of two types, the NVT balance and the NPT balance. At the end of both 
equilibrium situations, a fully balanced system was obtained at correct temperature and pressure 
conditions and the final production of the molecular dynamics was performed.
3.7. Generation of interaction diagrams 2D protein-ligand
In order to analyze the Dynamic Molecular results, 2D diagrams were generated using 
LigPlot+ (Wallace, Laskowski e Thornton, 1995). It helped to demonstrate the interactions 
present in the protein-ligand complexes.
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4. Results and Discussion
4.1. Generation of shape-based model
The molecular interactions between the ligand in complex with the Pv-NMT protein, 
observed in Figure 3, were taken from PDB file with Id: 4B13, enabled the construction of a 
virtual screening model based on the way shown in Figure 4. The 4B13 complex was chosen 
because all the molecules present in the PDB in complex with the P. vivax NMT protein have 
similar resolutions, allowing the any of these molecules to be used as a basis in the generation 
of the model, being a completely arbitrary choice. In Figure 3, it is important to note that the 
model has some important points of interaction, such as hydrogen bridges, salt bridges and pi 
interactions, indicated by black dashed lines. Also noted are some hydrophobic interactions 
indicated by the green solid line.
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Figure 3. Interaction of 4B13 ligand in complex with the NMT P.vivax. The black dashed lines indicate 
the hydrogen bonds, salt bridges and pi interaction; and the green solid lines represents the hydrophobic 
interactions. Fonte: https://www.rcsb.org/structure/4B13.
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Figure 4. Shape-based model built with the help of vROCS ligand model builder tool. This was the 
generated model based in the interactions presents in Figure 3, that is in focus the donors of electrons (blue spheres) 
that represents hydrogen bonds, acceptors (red spheres) and rings (green sphere) that represents the hydrophobic 
interactions.
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4.2. Generation of ligand conformer databases
Both database the DIVERSet™ Cl and the Zbd were properly treated through some steps 
like the filtering of undesirable compounds, protonation and deprotonation state with adjusts in 
pH and generation of tautomers and conformers. Thus, it was guaranteed that just compounds 
with desirable features for drugs was selected.
4.3. Virtual screening in compound database and validation
According to the 2D structure of inhibitors, six PDB files were chosen, which have 
already been validated in complex with PvNMT: 4B12, 4B13, 4B14, 4BBH, 4CAE and 4CAF. 
PharmaGist webserver was used to provide the most suitable pharmacophores for virtual 
prospecting along with their alignment. The chosen result exhibited score 36,000 and 6 ligands. 
The known inhibitors were based on (Bell et al., 2012), accounting ten structures which are 
listed in the (Figure 4), and all the structures were design using PubChem Draw Structure tool 
(Kim et al., 2016).
To predict the decoys through known inhibitors, was used the DUD-E webtool (Mysinger 
et al., 2012) (Figure 5). Decoys are structures that have similar proprieties with ligand but 
different chemical structures. To realize the docking, both decoys and actives structures were 
submitted using Omega (Hawkins et al., 2010) and QUACPAC, which consisted in removing 
undesirable molecules, generating tautomer, correcting the pKa to physiological pH 7.4. After 
that, 3D structures were generated using vRocs (Hawkins, Skillman e Nicholls, 2007). Sixteen 
queries were generated, being possible the manual editing of them, and validation of the model 
using decoys, actives and libraries. All models are listed in the Table 1.
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According the higher AUC (area under the curve), which means a simply probability that 
a randomly chosen active ligand bind instead of inactive ligand, was selected the model 13 
(Table 1). The ROC curve plot is shown in Figure 6.
PF-03402619
Cl
PF-00075634
Biphenyl derivatives
pf-03531814 Azetidinopyrimidines PF-03531549
PF-03665853
Benzimidazolemethylamines Glycinyl 3-aminopyrrolidines
Figure 5. Known inhibitors design using PubChem Draw tool.
Extracted by “Selective Inhibitors of Protozoan Protein N-myristoyltransferases as Starting Points for Tropical 
Disease Medicinal Chemistry Programs” (Bell et al., 2012).
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points
Query number Pharmacophore AUC
1 5 0.714
2 5 0.764
3 5 0.727
4 5 0.797
5 5 0.849
6 5 0.749
7 5 0.755
8 5 0.604
9 6 0.739
10 6 0.780
11 6 0.682
12 6 0.727
13 6 0.880
14 6 0.842
15 6 0.845
16 6 0.743
Table 1. Number of queries generated, pharmacophore points and AUC of the models.
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4.4. Molecular Anchorage and Evaluation
The best 500 compounds according to TanimotoCombo score were obtained from the 
virtual screening performed on vROCS. FRED (McGann, 2011) docking program was used to 
perform the molecular docking between PvNMT enzyme and the best 500 ligands of each 
library (cl and zbd). After docking, only the 1% best Chemgauss4 scored compounds were 
selected and submitted in the pkCSM analysis (Table 2 and 3).
20
ChemBridge - Cl
Table 2. Selected compounds with best score of the ChemBridge Cl library after molecular docking.
ZINC12 - Zbd
Ranking Molecule ID Chemgauss4
Score
1 ZINC20358414 -17.82
2 ZINC20589172 -17.28
3 ZINC19370024 -17.20
4 ZINC20358910 -16.73
5 ZINC20394331 -16.63
6 ZINC20391476 -15.82
7 ZINC19361186 -15.17
Table 3. Selected compounds with the best score of the ZINC12 Zbd library after 
molecular docking.
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4.5. Analysis of toxic properties in silico
PKCSM was used to evaluate the principal pharmacokinetics characteristics (ADMET) 
of the compounds. The importance of this step it's that through this analysis, it can be predicted 
if the potential inhibitors presents the suitable parameters to drug selection, aiming a possible 
administration in human organism. To analyze the Cl database, was selected eight molecules, 
according to the Table 2, and in the Zbd data base was selected seven molecules, according to 
the Table 3. The results after the processing in software is present in Table 4 e Table 5, being 
the Cl and Zbd database respectively. The results were judged by positive and negative 
pharmacokinetic characteristics, and in case of this work, was choose some in specific like 
AMES toxicity, Max tolerated dose (human), hERG I inhibitor, hERG II inhibitor, Oral Rate 
Acute Toxicity (LD50), Oral Rat Chronic Toxicity (LOAEL), Hepatotoxicity, Skin 
Sensitization and the Minnow toxicity.
Through these parameters, was possible to select the possible best compound in each 
library, being of Cl the second compound ID: 24675937 (2-isopropyl-N-{[2-(4-
methylpiperazin-1-yl)pyridin-3-yl]methyl}pyrimidine-4-carboxamide) in Table 4 and Zbd 
library was selected the sixth compound, id: ZINC20391476 (7-hydroxy-3-(3-
methoxyphenoxy)-8-[(4-methylpiperazin-1-yl)methyl]-2 (trifluoromethyl)chromen-4-one) in 
Table 5.
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24675937
ChemBridge ID AMES 
toxicity
Max.tolerated 
dose (human)
hERG I 
inhibitor
hERG II 
inhibitor
Oral Rat 
Acute 
Toxicity 
(LD50)
Oral Rat 
Chronic 
Toxicity 
(LOAEL)
Hepatoto 
xicity
Skin 
Sensitisation
Minnow 
toxicity
19371731 2.6
Yes -0.75 No Yes 1 2.08 Yes No 1.45
No -0.13 No Yes 1.54 Yes No
2.8
1
27045314
No
77009166
No 0.41
-0.28 No
No
Yes
Yes
30306998
No
19532149
No
0.22
-0.65
No
No
Yes
Yes
99428690
Yes 0.54 No Yes
48788186
2.8
1
2.2
8
2.6
3
2.6
8
2.0
2 0.6
1.44
1.68
2.68
0.34
Yes
Yes
Yes
Yes
No
No
No
No
No
No
2.14
2.09
1.49
0.59
2.12
-0.64
2.5
9
Table 4. Results generated in pkCSM analysis of the Cl library after docking and evaluation.
No 0.02 No Yes 0.89 Yes No 0.79
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ZINC ID
AMES 
toxicity
Oral Rat 
Max.tolerate Acute
d dose hERG I hERG II Toxicity
(human) inhibitor inhibitor (LD50)
Skin
Oral Rat Chronic Hepatoto Sensitisatio Minnow
Toxicity (LOAEL) xicity n toxicity
ZINC20358414
No -0.377 No Yes 2.915 1.108 Yes No
ZINC20589172
-0.69 No Yes 2.986 0.488 Yes No 3.201No
ZINC19370024
No -0.387 No Yes 3.001 1.084 Yes No 3.42
ZINC20358910
No -0.919 No Yes 3.173 0.661 Yes No 2.897
ZINC20394331
No -0.856 No Yes 3.222 0.822 Yes No 2.913
ZINC20391476
No 0.235 No Yes 2.517 1.78 No No 3.538
ZINC19361186
No 0.355 No Yes 3.111 1.707 No No 3.086
Table 5. Results generated in pkCSM analysis of the Zbd library after docking and evaluation.
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4.6. Molecular Dynamics
The molecular dynamics simulation was performed on two selected compounds extracts 
of pkCSM analyzes (ChemBridge: 24675937 and ZINC20391476) for a further and important 
validation to this work. With this step, three parameters were observed: Vacuum minimum 
energy, Hydrogen-bonding analysis and RMSD of the complex involved in dynamics (Kumar, 
Garg e Bharatam, 2015). As a first parameter, in the free energy calculation, both of compounds 
have shown a good result, showing free energy very similar to the original ligand (Figure 7 and 
8). That result showed that both of compounds present balance and stability.
Vacuum MM Energy
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Figure 7. The minimization energy plots that demonstrate the comportment of the Cl library compound 
(ChemBridge: 24675937) in relation of the original ligand in complex with the NMT to verify the stability of 
the system during the MD simulation.
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Figure 8. The minimization energy plots that demonstrate the comportment of the Zbd library compound 
(ZINC20391476) in relation of the original ligand in complex with the NMT to verify the stability of the system 
during the MD simulation.
About the hydrogen-bonding interactions, the results were very satisfactory. During the 
simulation the ligands have shown highly conserved interactions with the active site residues 
and both remain bound of active site of PvNMT. Both the compounds demonstrated a very 
similar hydrogen-bonding interaction to the original ligand of NMT (Figure 9 to Figure 12).
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Figure 9. Numbers of hydrogen bounds formed during the simulation that was formed into the active site of NMT.
In this plot was the number of hydrogen bounds of the ligand original in complex with the NMT.
Figure 10. Numbers of hydrogen bounds formed during the simulation that was formed into the active site 
of NMT. In this plot was the number of hydrogen bounds of (ChemBridge: 24675937) in complex with the NMT.
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Hydrogen bonds
Hydrogen bonds(zbd)
Figure 11. Numbers of hydrogen bounds formed during the simulation that was formed into the active site
of NMT. In this plot was the number of hydrogen bounds of (ZINC20391476) in complex with the NMT.
Hydrogen bonds(ligOriginal)
Hydrogen bonds(zbd)
Figure 12. Numbers of hydrogen bounds formed during the simulation that was formed into the active site 
of NMT. In this plot was compared the number of hydrogen bounds between the ligand original in complex with 
the NMT and the (ChemBridge: 24675937) and (ZINC20391476) during the MD simulation.
RMSD, the root-mean-square-deviation of atomic positions, is one of most used to 
identify the similarity criteria in structural biology, having direct relation to the stability analysis 
of the compound at the active site of the protein (Neveu et al., 2018). The results of this work 
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demonstrated that the compound (ChemBridge: 24675937) have shown a similar and stable 
comportment in relation of the original ligand and the protein only, in contrast the compound 
(ZINC20391476) have shown a higher deviation when compared to the other compounds, but 
even with this deviation it was still stable (Figure 13 to Figure 16).
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Figure 13. The RMSD plot comparing the root-mean-square deviation of atomic position. This plot 
demonstrated how was the RMSD of the original ligand, the protein only, the (ChemBridge: 24675937) and 
(ZINC20391476) during the MD simulation.
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Figure 14. The RMSD plot comparing the root-mean-square deviation of atomic position. This plot 
demonstrated how was the RMSD of the original ligand (4-{[2-(3-benzyl-1,2,4-oxadiazol-5-yl)-3-methyl-1- 
benzofuran-4-yl]oxy}piperidine) and the protein only (NMT) during the MD simulation.
Figure 15. The RMSD plot comparing the root-mean-square deviation of atomic position. This plot 
demonstrated how was the RMSD of the original ligand (4-{[2-(3-benzyl-1,2,4-oxadiazol-5-yl)-3-methyl-1- 
benzofuran-4-yl]oxy}piperidine), the protein only (NMT) and the (ChemBridge: 24675937) during the MD 
simulation.
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Figure 16. The RMSD plot comparing the root-mean-square deviation of atomic position. This plot 
demonstrated how was the RMSD of the original ligand (4-{[2-(3-benzyl-1,2,4-oxadiazol-5-yl)-3-methyl-1- 
benzofuran-4-yl]oxy}piperidine), the protein only (NMT) and the (ZINC20391476) during the MD simulation.
4.7. Generation of interaction diagrams 2D protein-ligand
The LigPlot + 2D tool was used to generate 2D interaction patterns of the ligand-protein 
complex resulting from molecular dynamics. During the molecular dynamics simulation, about 
1000 frames were generated per tested NMT complex (Cl and Zbd), and to demonstrate how 
the ligand interacted with the protein during the simulation, three main frames were saved: 
frame 0, demonstrating how the interaction was at the beginning of the dynamics, frame 500 
demonstrating how the interaction was in the midst of the dynamics and the frame 1000, 
observing how the interaction carried in the final part of the dynamics. To have a valid 
comparison parameter, the same was done with the original ligand ((4-{[2-(3-benzyl-1,2,4- 
oxadiazol-5-yl)-3-methyl-1-benzofuran-4-yl]oxy}piperidine) in complex with the PvNMT.
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Figure 17. This plot shown the interaction in the frame 0 between the ligand (ChemBridge: 24675937) with 
the NMT. The ligand is represented by the purple color in the protein active site, and the shapes in red brick 
represents the hydrophobic interactions during the MD.
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Figure 18. This plot shown the interaction in the frame 500 between the ligand (ChemBridge: 24675937) 
with the NMT. The ligand is represented by the purple color in the protein active site, the brown color represents 
the amino acids, the shapes in red brick represents the hydrophobic interactions and the green dashed lines 
represents the hydrogen bonds during the MD.
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Figure 19. This plot shown the interaction in the frame 1000 between the ligand (ChemBridge: 24675937) 
with the NMT. The ligand is represented by the purple color in the protein active site, the brown color represents 
the amino acids, the shapes in red brick represents the hydrophobic interactions and the green dashed lines 
represents the hydrogen bonds during the MD.
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Figure 20. This plot shown the interaction in the frame 0 between the ligand (ZINC20391476) with the 
NMT. The ligand is represented by the purple color in the protein active site, and the shapes in red brick represents 
the hydrophobic interactions during the MD.
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Figure 21. This plot shown the interaction in the frame 500 between the ligand (ZINC20391476) with the 
NMT. The ligand is represented by the purple color in the protein active site, the brown color represents the amino 
acids, the shapes in red brick represents the hydrophobic interactions and the green dashed lines represents the 
hydrogen bonds, during the MD.
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Figure 22. This plot shown the interaction in the frame 1000 between the ligand (ZINC20391476) with the 
NMT. The ligand is represented by the purple color in the protein active site and the shapes in red brick represents 
the hydrophobic interactions during the MD.
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Figure 23. This plot shown the interaction in the frame 0 between the original ligand (4-{[2-(3-benzyl-1,2,4- 
oxadiazol-5-yl)-3-methyl-1-benzofuran-4-yl]oxy}piperidine) with the NMT. The ligand is represented by the 
purple color in the protein active site, the brown color represents the amino acids, the shapes in red brick represents 
the hydrophobic interactions and the green dashed lines represents the hydrogen bonds, during the MD.
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Figure 24. This plot shown the interaction in the frame 500 between the original ligand (4-{[2-(3-benzyl- 
1,2,4-oxadiazol-5-yl)-3-methyl-1-benzofuran-4-yl]oxy}piperidine)  with the NMT. The ligand is represented by 
the purple color in the protein active site, the brown color represents the amino acids, the shapes in red brick 
represents the hydrophobic interactions and the green dashed lines represents the hydrogen bonds, during the MD.
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Figure 25. This plot shown the interaction in the frame 1000 between the original ligand (4-{[2-(3-benzyl- 
1,2,4-oxadiazol-5-yl)-3-methyl-1-benzofuran-4-yl]oxy}piperidine)  with the NMT. The ligand is represented by 
the purple color in the protein active site, the brown color represents the amino acids, the shapes in red brick 
represents the hydrophobic interactions and the green dashed lines represents the hydrogen bonds, during the MD.
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When analyzing the interactions in each frame, it was visualized that the compound 
(ChemBridge: 24675937) shown more hydrogen bonds interaction, both in frame 500 and 1000 
(Figures 18 and 19), while the compound (ZINC20391476) demonstrated this interaction just 
in frame 500 (Figure 21). Then, compared to the original ligand (4-{[2-(3-benzyl-1,2,4- 
oxadiazol-5-yl)-3-methyl-1-benzofuran-4-yl]oxy}piperidine) which demonstrated hydrogen 
bonds in all frames (Figures 23-25), it can be said that the compound (ChemBridge: 24675937) 
during the MD was more stable and it resembled to the original ligand, while the 
(ZINC20391476) was shown stable but with greater variation.
In order to improve the results, a possible alternative would be to further reduce the 
minimization energy in the vacuum, increasing the duration of the simulation in the system, in 
order to observe if there is a greater stability of the molecule within the complex with a longer 
time.
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5. Conclusion
In this work it was possible to create a shape-based model based on the structure of the 
ligands from a complex with the PvNMT, carry out virtual screening and molecular docking 
using ligand libraries and perform toxicity analyses on the best ligands. The toxicity analyses 
has showed two potential compounds to be used as inhibitors against Plasmodium vivax NMT.
The MD was performed to simulate a biological system and to show the atomic 
interactions between the protein-ligand inside a water box, in controlled pressure, temperature 
and pH. Thus, it was possible to obtain a balanced system, allowing for more detailed analyzes 
on the specificity and stability of the selected ligand in the active site of the protein.
By analyzing all the results presented, it was possible to obtain good indications that the 
ligands tested could act as inhibitors in complex with NMT. The Cl library compound 
(ChemBridge: 24675937) was better in relation to the Zbd library compound (ZINC20391476), 
having greater similarity with the original ligand (4-{[2-(3-benzyl-1,2,4-oxadiazol-5-yl)-3- 
methyl-1-benzofuran-4-yl]oxy}piperidine) and its interactions. Compound (ChemBridge: 
24675937) demonstrated good stability at the active site of the protein, with relevant hydrogen 
bonding interactions, which made the compound even more stable in the active site of the 
protein. Although (ZINC20391476) does not show similar results to that of the original ligand 
(4-{[2-(3-benzyl-1,2,4-oxadiazol-5-yl)-3-methyl-1-benzofuran-4-yl]oxy}piperidine), it is still 
a potential molecule to act as an inhibitor in complex with NMT, because it also reached certain 
stability during the simulation, requiring some adjustments such as: decrease of minimizing 
energy in vacuum and improvement in root-mean-square-deviation of atomic positions 
parameter.
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The tools used in the area of bioinformatics are extremely important and can optimize 
some analyzes, but these separately are not enough to fully validate such methodologies. In 
order to have a complete closure and full validation, it would be necessary to proceed to another 
step, which would be in vitro and in vivo tests. This work achieved the objective of finding 
possible effective inhibitors, and if synthesized and tested could help on the development of 
new drugs against malaria.
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